Literature DB >> 23685757

Effects of combined c-myc and Bmi-1 siRNAs on the growth and chemosensitivity of MG-63 osteosarcoma cells.

Xiankuan Xie1, Zhaoming Ye, Disheng Yang, Huiming Tao.   

Abstract

Osteosarcoma is the most common form of primary malignant bone tumor. Patients who are insensitive to chemotherapy treatment often have a poor prognosis. According to our previous study, recombinant adenovirus (Myc-AS) in combination with caffeine enhances the induction of apoptosis and the chemotherapeutic effects of cisplatin (CDDP) in MG-63 osteosarcoma cells. The present study aimed to investigate the combinational effects of the small interfering RNAs (siRNAs) c-myc and Bmi-1 on the growth and chemosensitivity of MG-63 osteosarcoma cells. The results indicated that the cell growth inhibition rates of MG-63 cells gradually increased with increasing concentrations of CDDP (P<0.05). This observation was consistent in the single and combined siRNA groups. At a concentration of 5.0 µg/ml CDDP, the growth inhibition rates were 53.3±5.2, 42.7±6.3 and 40.9±4.7% in the combined, c-myc and Bmi-1 siRNA groups, respectively. The cell growth inhibition rate in the combined siRNA group was higher than that observed in the two single siRNA groups (P<0.05). The cell apoptotic rate was 37.3±4.9% in the combined siRNA group, which was significantly higher than that observed in the c-myc (24.8±5.6%) and Bmi-1 siRNA groups (22.7±6.1%; P<0.05). These results suggest that the chemosensitivity of MG-63 cells to CDDP may be markedly enhanced in the siRNA combination group. A decrease in cell proliferation and increased cell apoptosis were also observed in the siRNA combination group. The present study may provide novel insights to further elucidate the pathogenesis and drug resistance mechanisms involved in osteosarcoma. It may also improve our understanding of the underlying mechanisms involved in chemotherapeutic sensitivity, and thus aid the development of future therapeutic strategies for the treatment of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685757     DOI: 10.3892/mmr.2013.1484

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Establishment and analysis of osteosarcoma cell sublines with different metastatic characteristics.

Authors:  Zhi Li; Youjun Li; Nan Wang; Lifeng Yang; Wei Zhao; Xiandong Zeng
Journal:  Tumour Biol       Date:  2014-05-27

2.  MicroRNA-561 inhibits gastric cancercell proliferation and invasion by downregulating c-Myc expression.

Authors:  Kun Qian; Binglang Mao; Wei Zhang; Huanwen Chen
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

3.  BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.

Authors:  Mehdi Hayat Shahi; Daniel York; Regina Gandour-Edwards; Sita S Withers; Roseline Holt; Robert B Rebhun
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

4.  BMI1 promotes osteosarcoma proliferation and metastasis by repressing the transcription of SIK1.

Authors:  Qiang Wang; Yinghui Wu; Meng Lin; Gaigai Wang; Jinyan Liu; Min Xie; Bo Zheng; Cong Shen; Jun Shen
Journal:  Cancer Cell Int       Date:  2022-03-27       Impact factor: 5.722

5.  Curcumin Derivative C086 Combined with Cisplatin Inhibits Proliferation of Osteosarcoma Cells.

Authors:  Xi Jiang; Yulin Huang
Journal:  Med Sci Monit       Date:  2020-07-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.